Neurology

Pfizer, Beam sign multi-target research collaboration for rare diseases

Pfizer and Beam Therapeutics have entered into an exclusive four-year research collaboration focused on in vivo base editing programmes for three targets for rare genetic diseases of liver, central nervous system, liver and muscle.

AgeX Therapeutics enters research collaboration with UCI

Biotechnology firm AgeX Therapeutics has announced a research collaboration with the University of California, Irvine (UCI) on research programme for exosome-based treatments for some brain disorders.

Recursion, Roche, Genentech collaborate in neuroscience, oncology

Recursion, a clinical-stage biotechnology company, has announced a collaboration with Roche and Genentech, a member of the Roche Group.

SciNeuro and Eli Lilly sign exclusive license agreement for alpha-synuclein in Greater China

Biopharmaceutical company SciNeuro Pharmaceuticals has signed an exclusive license agreement with Eli Lilly and Company for the development and commercialisation of alpha-synuclein targeted antibody therapies in Greater China.

Anima signs new strategic collaboration deal with Takeda

Anima Biotech has announced its new strategic collaboration deal with Takeda Pharmaceutical Company for the discovery and development of new medicines to combat genetically defined neurological diseases.

Takeda secures global rights to develop and commercialise soticlestat

Takeda Pharmaceutical Company has entered into an exclusive agreement to secure global rights from Ovid Therapeutics to develop and commercialise the investigational medicine soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).